CD274 and non-small cell lung carcinoma: We have also revealed the potential therapeutic value of targeting SMUG1, NTHL1, PARP3, NTRK1, YTHDF2, PDK1, CD274, HEY1, PDCD10 and MAGEA1 which are differentially expressed in cisplatin‐resistant NSCLC cells.